Yves Matthess

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

Valérie Gailus-Durner, Bertolt Kreft, Martin Klingenspor, 2011, Nature communications.

Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1

Sven Kappel, K. Strebhardt, M. Kaufmann, 2005, Oncogene.

Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery

Sven Becker, K. Strebhardt, Y. Matthess, 2015, Expert opinion on drug discovery.